Mikhail Eydelman - Dec 30, 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, Gen Counsel & Corp Sec
Signature
Mikhail Eydelman, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Dec 30, 2022
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 03:31 PM
Previous filing
Jun 9, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PCVX Common Stock 8.03K Dec 30, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +27.5K $0.00 27.5K Dec 30, 2022 Common Stock 27.5K $47.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 532 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2022.
F2 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.